A Phase 3 interventional study of Azilsartan medoxomil and chlorthalidone and Azilsartan medoxomil and chlorthalidone in Essential Hypertension, sponsored by Takeda. Completed at 80 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2012-03-13.
Sponsored by Takeda · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies testing azilsartan medoxomil in Essential Hypertension — none open to participants now, none under way, none of them phase 3. azilsartan medoxomil · Essential Hypertension.
Among the 11 studies testing azilsartan medoxomil in Essential Hypertension, this one is the 3rd largest by enrollment, is one of 3 that started in 2009, is one of 10 in phase 3, and was the 7th registered.
480 studies on the registry are indexed under Essential Hypertension; 76 are open to participants now.
Browse Essential Hypertension studies →None of the 11 studies testing azilsartan medoxomil in Essential Hypertension is open now. The open studies under Essential Hypertension, anywhere →
azilsartan medoxomil: first EMA approval 2011. What it is approved for, and how studies give it, is on its page →
Of the 45 Essential Hypertension studies recruiting now, 17 (38%) set no upper age limit and 20 (44%) stop at 75 or younger; 4 take children under 18; 11 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 3 started in 2009.
This study's enrollment of 1,085 is above the median of 144 across 407 interventional studies indexed under Essential Hypertension.
Median enrollment 837 across the 11 interventional studies. Of the 11 that completed or were terminated, 11 (100%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 11 have an industry lead sponsor. The 1 most frequent:
Takeda is the lead sponsor of 1,026 studies on the registry; 88 are open to participants now.
Of its 178 completed or terminated interventional studies of FDA-regulated products, 154 (87%) have results posted.
15 studies in Essential Hypertension by Takeda: none open now, none under way, none of them phase 3. Of 15 finished, 14 (93%) have results posted.
Among the 15 studies in Essential Hypertension by Takeda, this one is the 3rd largest by enrollment, is one of 3 that started in 2009, is one of 12 in phase 3, and was the 7th registered.
Takeda’s Essential Hypertension studies by the year they started, since 2007.
None of the studies under way reaches primary completion within a year.
Among the 11 studies testing azilsartan medoxomil in Essential Hypertension, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Takeda’s 15 in Essential Hypertension:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine the efficacy and safety of azilsartan medoxomil combined with chlorthalidone, once daily (QD), in participants with moderate to severe essential hypertension.
According to the World Health Organization, hypertension is the most common attributable cause of preventable death in developed nations, as uncontrolled hypertension greatly increases the risk of cardiovascular disease, cerebrovascular disease and renal failure. As the population ages, the prevalence of hypertension will continue to increase if broad and effective preventive measures are not implemented. Despite the availability of antihypertensive agents, hypertension remains inadequately controlled; only about one-third of patients continue to maintain control successfully.
Although most antihypertensive agents are effective at the appropriate dose, the majority have side effects that limit their use. As a class, angiotensin II receptor blockers generally are considered more tolerable than other classes of antihypertensive agents. TAK-491 (azilsartan medoxomil) is an angiotensin II receptor blocker being evaluated by Takeda to treat essential hypertension.
Treatments for essential hypertension commonly include use of a thiazide-like diuretic, either alone or as part of combination treatment. Although chlorthalidone was commonly prescribed in the past, its use has widely been replaced with hydrochlorothiazide, presumably due to a lack of available combination products containing chlorthalidone, the assumption that hydrochlorothiazide and chlorthalidone have similar antihypertensive effects and cardiovascular benefits, and the perception that chlorthalidone use is associated with a greater frequency of hypokalemia. However, the frequency of hypokalemia with chlorthalidone use is relatively low in the dose range of 12.5 to 25 mg and these doses have been shown to be associated with potent blood pressure reduction. Several long-term outcomes trials have shown that blood pressure reductions associated with chlorthalidone treatment reduce risk of cardiovascular morbidity and mortality.
Most hypertensive patients require two or more agents to achieve target blood pressure and diuretics are commonly used in combination with other antihypertensive agents.
Participants in this study will be randomized to receive one of 3 possible dosing combinations of azilsartan medoxomil with either chlorthalidone or olmesartan medoxomil-hydrochlorothiazide over 8 weeks. The total duration of the study is approximately 13 weeks. Participants will make a total of 11 visits to the clinic, and will be required to participate in a follow-up telephone call 14 days after last dose of the study drug for adverse event assessment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
(dependant on blood pressure)
Drug: Azilsartan medoxomil and chlorthalidone
(dependant on blood pressure)
Drug: Azilsartan medoxomil and chlorthalidone
(dependant on blood pressure)
Drug: Olmesartan medoxomil-hydrochlorothiazide
Drug pages: Azilsartan medoxomil · Chlorthalidone
Azilsartan medoxomil 20 mg and chlorthalidone 12.5 mg, tablets, orally, and olmesartan medoxomil-hydrochlorothiazide placebo tablets once daily for 8 weeks. If participant does not achieve target blood pressure at Week 4, then the dosage will be increased to azilsartan medoxomil 40 mg and chlorthalidone 25 mg, tablets, orally, once daily for the remaining 4 weeks.
Also known as: azilsartan medoxomil, chlorthalidone, TAK-491, TAK-491CLD
Drug pages: Azilsartan medoxomil · Chlorthalidone
Azilsartan medoxomil 40 mg and chlorthalidone 12.5, mg, tablets, orally, and olmesartan medoxomil-hydrochlorothiazide placebo tablets once daily for 8 weeks. If participant does not achieve target blood pressure at Week 4, then the dosage will be increased to azilsartan medoxomil 80 mg and chlorthalidone 25 mg, tablets, orally, once daily for the remaining 4 weeks.
Also known as: azilsartan medoxomil, chlorthalidone, TAK-491, TAK-491CLD
Olmesartan medoxomil 20 mg/hydrochlorothiazide 12.5 mg, tablets, orally, and Azilsartan medoxomil and chlorthalidone placebo-matching tablets, orally, once daily for 8 weeks. If participant does not achieve target blood pressure at Week 4, then the dosage will be increased to olmesartan medoxomil 40 mg/hydrochlorothiazide 25 mg, tablets, orally, once daily for the remaining 4 weeks.
Also known as: Benicar HCT®
Change From Baseline to Week 8 in Trough, Sitting, Clinic Systolic Blood Pressure.
The change in trough systolic blood pressure measured at week 8 or final visit relative to baseline. Systolic blood pressure is the average of the 3 serial trough sitting systolic blood pressure measurements.
Time frame: Baseline and Week 8.
Change From Baseline to Week 4 in Trough, Sitting, Clinic Systolic Blood Pressure.
The change in trough systolic blood pressure measured at week 4 relative to baseline. Systolic blood pressure is the average of the 3 serial trough sitting systolic blood pressure measurements.
Time frame: Baseline and Week 4.
Change From Baseline in Trough, Sitting, Clinic Diastolic Blood Pressure
The change in trough diastolic blood pressure measured at week 4 and week 8 relative to baseline. Diastolic blood pressure is the average of the 3 serial trough sitting diastolic blood pressure measurements.
Time frame: Baseline, Week 4 and Week 8.
Change From Baseline in Trough Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
The change in trough systolic blood pressure measured at week 4 and week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Trough is the average of all measurements recorded from 22 to 24 hours after dosing.
Time frame: Baseline, Week 4 and Week 8.
Change From Baseline in Trough Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
The change in trough systolic blood pressure measured at week 4 and week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Trough is the average of all measurements recorded from 22 to 24 hours after dosing.
Time frame: Baseline, Week 4 and Week 8.
Change From Baseline in 24-hour Mean Systolic Blood Pressure as Measured by Ambulatory Blood Pressure Monitoring.
The change in the 24-hour mean systolic blood pressure at week4 and week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 24-hour mean is the average of all measurements recorded for 24 hours after dosing.
Time frame: Baseline, Week 4 and Week 8.
Change From Baseline in 24-hour Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
The change in the 0 to 24-hours-after-dosing mean diastolic blood pressure measured at Week 4 and Week 8 relative to baseline. . Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The mean consists of the average of measurements collected over the subsequent 24 hours.
Time frame: Baseline, Week 4 and Week 8.
Change From Baseline in Daytime Mean (6am to 10pm) Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
The change in the daytime, while awake (6am to 10pm) mean systolic blood pressure measured at Week 4 and Week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night Daytime mean is the average of measurements recorded between the hours of 6 AM (inclusive) and 10 PM (exclusive) included in the 24-hour mean calculations.
Time frame: Baseline, Week 4 and Week 8.
Change From Baseline in Daytime Mean (6am to 10pm) Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
The change in the daytime, while awake (6am to 10pm) mean diastolic blood pressure measured at Week 4 and Week 8relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Daytime mean is the average of measurements recorded between the hours of 6 AM (inclusive) and 10 PM (exclusive) included in the 24-hour mean calculations.
Time frame: Baseline, Week 4 and Week 8.
Change From Baseline in Nighttime Mean (12am to 6am) Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring
The change in the nighttime, while asleep (12am to 6am) mean systolic blood pressure measured at Week 4 and Week 8 to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Nighttime mean is the average of measurements recorded between the hours of 12 AM (inclusive) and 6 AM (exclusive) included in the 24-hour mean calculations.
Time frame: Baseline, Week 4 and Week 8.
Change From Baseline in Nighttime Mean (12am to 6am) Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
The change in the nighttime, while asleep (12am to 6am) mean diastolic blood pressure measured at Week 4 and Week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Nighttime mean is the average (arithmetic mean) of measurements recorded between the hours of 12 AM (inclusive) and 6 AM (exclusive) included in the 24-hour mean calculations.
Time frame: Baseline, Week 4 and Week 8.
Change From Baseline in 12-hr Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
The change in the 0 to 12 hours-after-dosing mean Systolic Blood Pressure measured at Week 4 and Week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night The mean consists of the average (arithmetic mean) of measurements collected at each time frame and includes all observations recorded over the subsequent 12 hours.
Time frame: Baseline, Week 4 and Week 8.
Change From Baseline in 12-hr Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
The change in the 0 to 12 hours-after-dosing mean diastolic blood pressure measured at Week 4 and Week 8 to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The mean consists of the average (arithmetic mean) of measurements collected at each time frame and includes all observations recorded over the subsequent 12 hours.
Time frame: Baseline, Week 4 and Week 8.
Percentage of Participants Who Achieve a Clinic Systolic Blood Pressure Response, Defined as <140 mm Hg for Participants Without Diabetes or CKD or <130 mm Hg for Participants With Diabetes or CKD
Percentage of participants who achieve a clinic systolic blood pressure response, defined as \<140 mm Hg for participants without diabetes or CKD or \<130 mm Hg for participants with diabetes or CKD at each time frame relative to baseline.
Time frame: Baseline, Week 2, Week 4, Week 6 and Week 8.
Percentage of Participants Who Achieve a Clinic Diastolic Blood Pressure Response, Defined as Defined as <90 mm Hg for Participants Without Diabetes or CKD or <80 mm Hg for Participants With Diabetes or CKD
Percentage of participants who achieve a clinic diastolic blood pressure response, defined as defined as \<90 mm Hg for participants without diabetes or CKD or \<80 mm Hg for participants with diabetes or CKD at each time frame relative to baseline.
Time frame: Baseline, Week 2, Week 4, Week 6 and Week 8.
Percentage of Participants Who Achieve a Clinic Diastolic AND Systolic Blood Pressure Response, Defined as <140/90 mm Hg for Participants Without Diabetes or Chronic Kidney Disease (CKD) or <130/80 mm Hg for Participants With Diabetes or CKD
Percentage of participants who achieve both a clinic diastolic blood pressure response, defined as \<140/90 mm Hg for participants without diabetes or chronic kidney disease (CKD) or \<130/80 mm Hg for participants with diabetes or CKD at each time frame relative to baseline.
Time frame: Baseline, Week 2, Week 4, Week 6 and Week 8.
Participants enrolled at 93 investigative sites in Argentina, Chile, Mexico and the United States from 13 March 2009 to 25 June 2010.
| Milestone | Azilsartan Medoxomil 20-40mg Plus Chlorthalidone 12.5-25 mg QD | Azilsartan Medoxomil 40-80mg Plus Chlorthalidone 12.5-25 mg QD | Olmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD |
|---|---|---|---|
| Started | 372 | 357 | 356 |
| Completed | 317 | 308 | 323 |
| Not completed | 55 | 49 | 33 |
| Withdrew: Adverse event | 20 | 30 | 11 |
| Withdrew: Protocol violation | 5 | 4 | 0 |
| Withdrew: Lost to follow-up | 8 | 2 | 5 |
| Withdrew: Withdrawal by subject | 11 | 11 | 9 |
| Withdrew: Pregnancy | 1 | 0 | 0 |
| Withdrew: Lack of efficacy | 1 | 1 | 2 |
| Withdrew: Other | 9 | 1 | 6 |
The change in trough systolic blood pressure measured at week 8 or final visit relative to baseline. Systolic blood pressure is the average of the 3 serial trough sitting systolic blood pressure measurements.
| mmHg | Azilsartan Medoxomil 20-40mg Plus Chlorthalidone 12.5-25 mg QD | Azilsartan Medoxomil 40-80mg Plus Chlorthalidone 12.5-25 mg QD | Olmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD |
|---|---|---|---|
| Change From Baseline to Week 8 in Trough, Sitting, Clinic Systolic Blood Pressure. | -37.6 ± 0.83 | -38.2 ± 0.85 | -31.5 ± 0.84 |
The change in trough systolic blood pressure measured at week 4 relative to baseline. Systolic blood pressure is the average of the 3 serial trough sitting systolic blood pressure measurements.
| mmHg | Azilsartan Medoxomil 20-40mg Plus Chlorthalidone 12.5-25 mg QD | Azilsartan Medoxomil 40-80mg Plus Chlorthalidone 12.5-25 mg QD | Olmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD |
|---|---|---|---|
| Change From Baseline to Week 4 in Trough, Sitting, Clinic Systolic Blood Pressure. | -33.0 ± 0.87 | -34.1 ± 0.88 | -26.9 ± 0.88 |
The change in trough diastolic blood pressure measured at week 4 and week 8 relative to baseline. Diastolic blood pressure is the average of the 3 serial trough sitting diastolic blood pressure measurements.
| mmHg | Azilsartan Medoxomil 20-40mg Plus Chlorthalidone 12.5-25 mg QD | Azilsartan Medoxomil 40-80mg Plus Chlorthalidone 12.5-25 mg QD | Olmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD |
|---|---|---|---|
| Week 4 (n=360; n=347; n=352) | -13.6 ± 0.49 | -14.2 ± 0.50 | -10.4 ± 0.49 |
| Week 8 (n=363; n=350; n=353) | -16.1 ± 0.47 | -16.5 ± 0.48 | -12.8 ± 0.48 |
The change in trough systolic blood pressure measured at week 4 and week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Trough is the average of all measurements recorded from 22 to 24 hours after dosing.
| mmHg | Azilsartan Medoxomil 20-40mg Plus Chlorthalidone 12.5-25 mg QD | Azilsartan Medoxomil 40-80mg Plus Chlorthalidone 12.5-25 mg QD | Olmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD |
|---|---|---|---|
| Week 4 (n=223; n=227; n=219) | -22.4 ± 0.95 | -23.6 ± 0.94 | -17.4 ± 0.96 |
| Week 8 (n=290; n=278; n=281) | -24.9 ± 0.79 | -26.8 ± 0.81 | -19.6 ± 0.80 |
The change in trough systolic blood pressure measured at week 4 and week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Trough is the average of all measurements recorded from 22 to 24 hours after dosing.
| mmHg | Azilsartan Medoxomil 20-40mg Plus Chlorthalidone 12.5-25 mg QD | Azilsartan Medoxomil 40-80mg Plus Chlorthalidone 12.5-25 mg QD | Olmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD |
|---|---|---|---|
| Week 4 (n=223; n=227; n=219) | -13.4 ± 0.66 | -14.6 ± 0.66 | -10.9 ± 0.67 |
| Week 8 (n=290; n=278; n=281) | -14.6 ± 0.56 | -15.9 ± 0.57 | -12.0 ± 0.57 |
The change in the 24-hour mean systolic blood pressure at week4 and week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 24-hour mean is the average of all measurements recorded for 24 hours after dosing.
| mmHg | Azilsartan Medoxomil 20-40mg Plus Chlorthalidone 12.5-25 mg QD | Azilsartan Medoxomil 40-80mg Plus Chlorthalidone 12.5-25 mg QD | Olmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD |
|---|---|---|---|
| Week 4 (n=223; n=227; n=219) | -24.1 ± 0.81 | -24.4 ± 0.80 | -18.4 ± 0.81 |
| Week 8 (n=290; n=278; n=281) | -26.4 ± 0.69 | -27.9 ± 0.70 | -20.7 ± 0.70 |
The change in the 0 to 24-hours-after-dosing mean diastolic blood pressure measured at Week 4 and Week 8 relative to baseline. . Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The mean consists of the average of measurements collected over the subsequent 24 hours.
| mmHg | Azilsartan Medoxomil 20-40mg Plus Chlorthalidone 12.5-25 mg QD | Azilsartan Medoxomil 40-80mg Plus Chlorthalidone 12.5-25 mg QD | Olmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD |
|---|---|---|---|
| Week 4 (n=223; n=227; n=219) | -13.9 ± 0.51 | -14.4 ± 0.51 | -10.5 ± 0.52 |
| Week 8 (n=290; n=278; n=281) | -15.1 ± 0.45 | -16.4 ± 0.46 | -12.0 ± 0.46 |
The change in the daytime, while awake (6am to 10pm) mean systolic blood pressure measured at Week 4 and Week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night Daytime mean is the average of measurements recorded between the hours of 6 AM (inclusive) and 10 PM (exclusive) included in the 24-hour mean calculations.
| mmHg | Azilsartan Medoxomil 20-40mg Plus Chlorthalidone 12.5-25 mg QD | Azilsartan Medoxomil 40-80mg Plus Chlorthalidone 12.5-25 mg QD | Olmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD |
|---|---|---|---|
| Week 4 (n=223; n=227; n=219) | -24.5 ± 0.84 | -25.1 ± 0.83 | -18.9 ± 0.85 |
| Week 8 (n=290; n=278; n=281) | -26.7 ± 0.72 | -28.4 ± 0.74 | -21.0 ± 0.74 |
The change in the daytime, while awake (6am to 10pm) mean diastolic blood pressure measured at Week 4 and Week 8relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Daytime mean is the average of measurements recorded between the hours of 6 AM (inclusive) and 10 PM (exclusive) included in the 24-hour mean calculations.
| mmHg | Azilsartan Medoxomil 20-40mg Plus Chlorthalidone 12.5-25 mg QD | Azilsartan Medoxomil 40-80mg Plus Chlorthalidone 12.5-25 mg QD | Olmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD |
|---|---|---|---|
| Week 4 (n=223; n=227; n=219) | -14.2 ± 0.53 | -14.7 ± 0.53 | -10.7 ± 0.54 |
| Week 8 (n=290; n=278; n=281) | -15.3 ± 0.47 | -16.6 ± 0.48 | -12.1 ± 0.48 |
The change in the nighttime, while asleep (12am to 6am) mean systolic blood pressure measured at Week 4 and Week 8 to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Nighttime mean is the average of measurements recorded between the hours of 12 AM (inclusive) and 6 AM (exclusive) included in the 24-hour mean calculations.
| mmHg | Azilsartan Medoxomil 20-40mg Plus Chlorthalidone 12.5-25 mg QD | Azilsartan Medoxomil 40-80mg Plus Chlorthalidone 12.5-25 mg QD | Olmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD |
|---|---|---|---|
| Week 4 (n=223; n=227; n=219) | -22.3 ± 0.87 | -21.9 ± 0.86 | -16.6 ± 0.88 |
| Week 8 (n=290; n=278; n=281) | -25.2 ± 0.74 | -26.3 ± 0.75 | -19.7 ± 0.75 |
The change in the nighttime, while asleep (12am to 6am) mean diastolic blood pressure measured at Week 4 and Week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Nighttime mean is the average (arithmetic mean) of measurements recorded between the hours of 12 AM (inclusive) and 6 AM (exclusive) included in the 24-hour mean calculations.
| mmHg | Azilsartan Medoxomil 20-40mg Plus Chlorthalidone 12.5-25 mg QD | Azilsartan Medoxomil 40-80mg Plus Chlorthalidone 12.5-25 mg QD | Olmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD |
|---|---|---|---|
| Week 4 (n=223; n=227; n=219) | -13.4 ± 0.58 | -13.3 ± 0.58 | -9.6 ± 0.59 |
| Week 8 (n=290; n=278; n=281) | -14.9 ± 0.51 | -15.8 ± 0.52 | -11.8 ± 0.52 |
The change in the 0 to 12 hours-after-dosing mean Systolic Blood Pressure measured at Week 4 and Week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night The mean consists of the average (arithmetic mean) of measurements collected at each time frame and includes all observations recorded over the subsequent 12 hours.
| mmHg | Azilsartan Medoxomil 20-40mg Plus Chlorthalidone 12.5-25 mg QD | Azilsartan Medoxomil 40-80mg Plus Chlorthalidone 12.5-25 mg QD | Olmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD |
|---|---|---|---|
| Week 4 (n=223; n=227; n=219) | -25.0 ± 0.87 | -25.5 ± 0.86 | -19.2 ± 0.88 |
| Week 8 (n=290; n=278; n=281) | -27.1 ± 0.77 | -28.8 ± 0.78 | -21.1 ± 0.78 |
The change in the 0 to 12 hours-after-dosing mean diastolic blood pressure measured at Week 4 and Week 8 to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The mean consists of the average (arithmetic mean) of measurements collected at each time frame and includes all observations recorded over the subsequent 12 hours.
| mmHg | Azilsartan Medoxomil 20-40mg Plus Chlorthalidone 12.5-25 mg QD | Azilsartan Medoxomil 40-80mg Plus Chlorthalidone 12.5-25 mg QD | Olmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD |
|---|---|---|---|
| Week 4 (n=223; n=227; n=219) | -14.4 ± 0.56 | -14.8 ± 0.55 | -10.8 ± 0.56 |
| Week 8 (n=290; n=278; n=281) | -15.4 ± 0.50 | -16.9 ± 0.51 | -12.1 ± 0.51 |
Percentage of participants who achieve a clinic systolic blood pressure response, defined as \<140 mm Hg for participants without diabetes or CKD or \<130 mm Hg for participants with diabetes or CKD at each time frame relative to baseline.
| percentage of participants | Azilsartan Medoxomil 20-40mg Plus Chlorthalidone 12.5-25 mg QD | Azilsartan Medoxomil 40-80mg Plus Chlorthalidone 12.5-25 mg QD | Olmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD |
|---|---|---|---|
| Week 2 (n=343; n=334; n=345) | 60.3 | 57.2 | 44.9 |
| Week 4 (n=360; n=347; n=352) | 66.1 | 68.9 | 52.3 |
| Week 6 (n=362; n=350; n=353) | 76.8 | 73.4 | 64.9 |
| Week 8 (n=363; n=350; n=353) | 76.0 | 76.0 | 64.6 |
Percentage of participants who achieve a clinic diastolic blood pressure response, defined as defined as \<90 mm Hg for participants without diabetes or CKD or \<80 mm Hg for participants with diabetes or CKD at each time frame relative to baseline.
| percentage of participants | Azilsartan Medoxomil 20-40mg Plus Chlorthalidone 12.5-25 mg QD | Azilsartan Medoxomil 40-80mg Plus Chlorthalidone 12.5-25 mg QD | Olmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD |
|---|---|---|---|
| Week 2 (n=343; n=334; n=345) | 63.6 | 66.2 | 47.8 |
| Week 4 (n=360; n=347; n=352) | 71.4 | 73.8 | 58.2 |
| Week 6 (n=362; n=350; n=353) | 77.9 | 76.9 | 66.9 |
| Week 8 (n=363; n=350; n=353) | 79.9 | 79.1 | 66.0 |
Percentage of participants who achieve both a clinic diastolic blood pressure response, defined as \<140/90 mm Hg for participants without diabetes or chronic kidney disease (CKD) or \<130/80 mm Hg for participants with diabetes or CKD at each time frame relative to baseline.
| percentage of participants | Azilsartan Medoxomil 20-40mg Plus Chlorthalidone 12.5-25 mg QD | Azilsartan Medoxomil 40-80mg Plus Chlorthalidone 12.5-25 mg QD | Olmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD |
|---|---|---|---|
| Week 2 (n=343; n=334; n=345) | 51.3 | 48.5 | 35.9 |
| Week 4 (n=360; n=347; n=352) | 58.1 | 61.4 | 44.6 |
| Week 6 (n=362; n=350; n=353) | 68.8 | 65.4 | 55.5 |
| Week 8 (n=363; n=350; n=353) | 69.4 | 68.9 | 54.7 |
Collected over Treatment-emergent adverse events are adverse events that started on or after the first dose of double-blind study drug and no more than 14 days (or 30 days for a serious adverse event) after the last dose of double-blind study drug.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Azilsartan Medoxomil 20-40mg Plus Chlorthalidone 12.5-25 mg QD | — | 4/372 (1.1%) | 66/372 (17.7%) |
| Azilsartan Medoxomil 40-80mg Plus Chlorthalidone 12.5-25 mg QD | — | 8/357 (2.2%) | 72/357 (20.2%) |
| Olmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD | — | 6/356 (1.7%) | 56/356 (15.7%) |
| Event | Azilsartan Medoxomil 20-40mg Plus Chlorthalidone 12.5-25 mg QD | Azilsartan Medoxomil 40-80mg Plus Chlorthalidone 12.5-25 mg QD | Olmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD |
|---|---|---|---|
| Cardiac arrestCardiac disorders | 0/372 | 1/357 | 1/356 |
| Coronary artery diseaseCardiac disorders | 0/372 | 0/357 | 1/356 |
| Chest painGeneral disorders | 0/372 | 0/357 | 1/356 |
| Systemic inflammatory response syndromeGeneral disorders | 0/372 | 0/357 | 1/356 |
| CellulitisInfections and infestations | 0/372 | 1/357 | 1/356 |
| Heat exhaustionInjury, poisoning and procedural complications | 0/372 | 0/357 | 1/356 |
| Troponin increasedInvestigations | 0/372 | 0/357 | 1/356 |
| DehydrationMetabolism and nutrition disorders | 0/372 | 0/357 | 1/356 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 1/372 | 0/357 | 1/356 |
| AsthmaRespiratory, thoracic and mediastinal disorders | 0/372 | 0/357 | 1/356 |
| Event | Azilsartan Medoxomil 20-40mg Plus Chlorthalidone 12.5-25 mg QD | Azilsartan Medoxomil 40-80mg Plus Chlorthalidone 12.5-25 mg QD | Olmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD |
|---|---|---|---|
| Blood creatinine increasedInvestigations | 36/372 | 44/357 | 25/356 |
| DizzinessNervous system disorders | 25/372 | 24/357 | 20/356 |
| HeadacheNervous system disorders | 14/372 | 14/357 | 18/356 |
| Age Continuous(years) | Azilsartan Medoxomil 20-40mg Plus Chlorthalidone 12.5-25 mg QD | Azilsartan Medoxomil 40-80mg Plus Chlorthalidone 12.5-25 mg QD | Olmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD | Total |
|---|---|---|---|---|
| Mean | 55.5 ± 10.49 | 56.7 ± 10.83 | 55.7 ± 9.78 | 56.0 ± 10.38 |
| Age, Customized(participants) | Azilsartan Medoxomil 20-40mg Plus Chlorthalidone 12.5-25 mg QD | Azilsartan Medoxomil 40-80mg Plus Chlorthalidone 12.5-25 mg QD | Olmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD | Total |
|---|---|---|---|---|
| <45 years | 47 | 38 | 41 | 126 |
| 45 to 64 years | 252 | 244 | 249 | 745 |
| ≥65 years | 73 | 75 | 66 | 214 |
| Sex: Female, Male(Participants) | Azilsartan Medoxomil 20-40mg Plus Chlorthalidone 12.5-25 mg QD | Azilsartan Medoxomil 40-80mg Plus Chlorthalidone 12.5-25 mg QD | Olmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD | Total |
|---|---|---|---|---|
| Female | 175 | 174 | 173 | 522 |
| Male | 197 | 183 | 183 | 563 |
| Ethnicity (NIH/OMB)(Participants) | Azilsartan Medoxomil 20-40mg Plus Chlorthalidone 12.5-25 mg QD | Azilsartan Medoxomil 40-80mg Plus Chlorthalidone 12.5-25 mg QD | Olmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD | Total |
|---|---|---|---|---|
| Hispanic or Latino | 37 | 41 | 44 | 122 |
| Not Hispanic or Latino | 265 | 253 | 251 | 769 |
| Unknown or Not Reported | 70 | 63 | 61 | 194 |
| Race (NIH/OMB)(participants) | Azilsartan Medoxomil 20-40mg Plus Chlorthalidone 12.5-25 mg QD | Azilsartan Medoxomil 40-80mg Plus Chlorthalidone 12.5-25 mg QD | Olmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 37 | 34 | 35 | 106 |
| Asian | 7 | 5 | 5 | 17 |
| Native Hawaiian or Other Pacific Islander | 3 | 0 | 0 | 3 |
| Black or African American | 95 | 95 | 100 | 290 |
| White | 235 | 225 | 220 | 680 |
| More than one race | 5 | 2 | 4 | 11 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Region of Enrollment(participants) | Azilsartan Medoxomil 20-40mg Plus Chlorthalidone 12.5-25 mg QD | Azilsartan Medoxomil 40-80mg Plus Chlorthalidone 12.5-25 mg QD | Olmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD | Total |
|---|---|---|---|---|
| United States | 302 | 294 | 295 | 891 |
| Mexico | 45 | 44 | 43 | 132 |
| Chile | 12 | 10 | 9 | 31 |
| Argentina | 13 | 9 | 9 | 31 |
| Weight(kg) | Azilsartan Medoxomil 20-40mg Plus Chlorthalidone 12.5-25 mg QD | Azilsartan Medoxomil 40-80mg Plus Chlorthalidone 12.5-25 mg QD | Olmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD | Total |
|---|---|---|---|---|
| Mean | 89.35 ± 20.995 | 89.87 ± 21.281 | 90.66 ± 20.700 | 89.95 ± 20.981 |
| Height(cm) | Azilsartan Medoxomil 20-40mg Plus Chlorthalidone 12.5-25 mg QD | Azilsartan Medoxomil 40-80mg Plus Chlorthalidone 12.5-25 mg QD | Olmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD | Total |
|---|---|---|---|---|
| Mean | 167.5 ± 11.22 | 167.8 ± 11.06 | 168.2 ± 10.30 | 167.8 ± 10.87 |
4 further baseline measures are reported on the registry.
The record gives a start of Mar 2009, a primary completion of Jun 2010 and a completion of Jun 2010. It does not say whether these dates are actual or estimated.
Results were first posted in Mar 2012, 1 year 9 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Azilsartan medoxomil · Chlorthalidone